These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24703530)

  • 1. Exploring better strategies for EGFR antibodies in colon cancer.
    Cervantes A
    Lancet Oncol; 2014 May; 15(6):549-50. PubMed ID: 24703530
    [No Abstract]   [Full Text] [Related]  

  • 2. How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
    Lindsay CR; Roxburgh P; Graham J
    Future Oncol; 2013 Jun; 9(6):825-9. PubMed ID: 23718303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line therapy for metastatic colorectal cancer.
    Price TJ
    Lancet Oncol; 2015 May; 16(5):476-7. PubMed ID: 25877856
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug combo beneficial in colorectal cancer.
    Cancer Discov; 2015 Feb; 5(2):102. PubMed ID: 25656881
    [No Abstract]   [Full Text] [Related]  

  • 5. Always look at the bright side of drugs?
    Nygren P
    Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
    [No Abstract]   [Full Text] [Related]  

  • 6. Cetuximab in colon cancer.
    Costa AF; Sander GB; Picon PD
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473024
    [No Abstract]   [Full Text] [Related]  

  • 7. Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies.
    Marshall JL
    J Clin Oncol; 2012 Aug; 30(23):2815-6. PubMed ID: 22753919
    [No Abstract]   [Full Text] [Related]  

  • 8. Cetuximab in colon cancer.
    Martin MJ
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
    Burtness B
    Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy for colorectal cancer.
    Marshall JL
    Oncology (Williston Park); 2014 Apr; 28(4):322, 324. PubMed ID: 24839806
    [No Abstract]   [Full Text] [Related]  

  • 11. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab in colon cancer.
    Giuliani F; Colucci G
    Int J Biol Markers; 2007; 22(1 Suppl 4):S62-70. PubMed ID: 17520583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.
    Negri FV; Musolino A; Naldi N; Bortesi B; Missale G; Laccabue D; Zerbini A; Camisa R; Chernyschova N; Bisagni G; Loupakis F; Ruzzo A; Neri TM; Ardizzoni A
    Pharmacogenomics J; 2014 Feb; 14(1):14-9. PubMed ID: 23296156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods of overcoming treatment resistance in colorectal cancer.
    Temraz S; Mukherji D; Alameddine R; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):217-30. PubMed ID: 24075059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [First/second/third-line chemotherapy with molecular targeted drugs for colorectal cancer].
    Sato A; Nakamachi M; Imataka H
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1242-6. PubMed ID: 19692761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
    J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Colorectal cancer: irinotecan in combination with newer drugs].
    Falcone A
    Tumori; 2001; 87(6):A31-3. PubMed ID: 11995705
    [No Abstract]   [Full Text] [Related]  

  • 19. Cetuximab or bevacizumab in metastatic colorectal cancer?
    Sclafani F; Cunningham D
    Lancet Oncol; 2014 Sep; 15(10):1040-1. PubMed ID: 25088941
    [No Abstract]   [Full Text] [Related]  

  • 20. An alternative therapy for patients with hepatic impairment?
    Choo SP; Venook AP
    Onkologie; 2007 Oct; 30(10):474-5. PubMed ID: 17890884
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.